Inovio Pharmaceuticals (GBM) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ino-9112, Cellectra® 2000, Ino-4800 | Coronavirus Infection | Phase I | Withdrawn | Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers | Jun 21, 2022 | ― |
| Cellectra® 2000, Ino-4800 | Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2), Covid-19 Disease | phase2AndPhase3 | Terminated | Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure | Nov 23, 2020 | ― |
| Cellectra™ 2000, Ino-4700 | Middle East Respiratory Syndrome Coronavirus (Mers-Cov) | Phase II | Completed | Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers | Oct 06, 2020 | ― |
| Cellectra™ 2000, Ino-3107 | Respiratory Papillomatosis | phase1AndPhase2 | Completed | INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) | May 14, 2020 | ― |
| Cellectra® 2000, Ino-4800 | Coronavirus Infection | Phase I | Completed | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | Apr 03, 2020 | ― |
| Ino-4500, Cellectra™ 2000 | Lassa Fever | Phase I | Completed | Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana | Sep 16, 2019 | ― |
| Ino-4500, Cellectra® 2000 | Lassa Fever | Phase I | Completed | Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers | Jan 14, 2019 | ― |
| Vgx-3100, Cellectra™-5Psp | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, Hsil | Phase III | Completed | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | Oct 25, 2018 | ― |
| Gls-6150 | Hcv Infection | Phase I | Completed | Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection | Sep 14, 2018 | ― |
| Gls-5300, Cellectra 2000 Electroporation | Healthy | phase1AndPhase2 | Completed | Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers | Sep 11, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ino-9112, Cellectra® 2000, Ino-4800 | Phase I | Coronavirus Infection | Withdrawn | Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers | Jun 21, 2022 | ― |
| Cellectra® 2000, Ino-4800 | phase2AndPhase3 | Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2), Covid-19 Disease | Terminated | Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure | Nov 23, 2020 | ― |
| Cellectra™ 2000, Ino-4700 | Phase II | Middle East Respiratory Syndrome Coronavirus (Mers-Cov) | Completed | Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers | Oct 06, 2020 | ― |
| Cellectra™ 2000, Ino-3107 | phase1AndPhase2 | Respiratory Papillomatosis | Completed | INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) | May 14, 2020 | ― |
| Cellectra® 2000, Ino-4800 | Phase I | Coronavirus Infection | Completed | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | Apr 03, 2020 | ― |
| Ino-4500, Cellectra™ 2000 | Phase I | Lassa Fever | Completed | Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana | Sep 16, 2019 | ― |
| Ino-4500, Cellectra® 2000 | Phase I | Lassa Fever | Completed | Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers | Jan 14, 2019 | ― |
| Vgx-3100, Cellectra™-5Psp | Phase III | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, Hsil | Completed | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | Oct 25, 2018 | ― |
| Gls-6150 | Phase I | Hcv Infection | Completed | Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection | Sep 14, 2018 | ― |
| Gls-5300, Cellectra 2000 Electroporation | phase1AndPhase2 | Healthy | Completed | Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers | Sep 11, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Inovio Pharmaceuticals (CH:GBM) have in its pipeline
Inovio Pharmaceuticals CH:GBM is currently developing the following drugs: Ino-9112, Cellectra® 2000, Ino-4800, Cellectra® 2000, Ino-4800, Cellectra™ 2000, Ino-4700, Cellectra™ 2000, Ino-3107, Ino-4500, Cellectra™ 2000, Ino-4500, Cellectra® 2000, Vgx-3100, Cellectra™-5Psp, Gls-6150, Gls-5300, Cellectra 2000 Electroporation, Ino-5401, Ino-9012, Atezolizumab, Cellectra™ 2000, Vgx-3100, Cellectra™ 5Psp, Cemiplimab, Temozolomide, Ino-5401, Ino-9012, Radiation Therapy, Vgx-3100, Electroporation (Ep), Vgx-3100, Cellectra™ 2000, Imiquimod 5% Cream, Ino-9012, Ino-1400, Ino-1401, Gls-5700, Gls-5300, 2Mg Ino-5150 And Electroporation Device Cellectra®-5P, 8.5Mg Ino-5150 And Electroporation Device Cellectra®-5P, 2Mg Ino-5150 Plus 1Mg Ino-9012 And Electroporation Device Cellectra®-5P, 8.5Mg Ino-5150 Plus 1Mg Ino-9012 And Electroporation Device Cellectra®-5P, Electroporation Using Cellectra®-5P, Ino-4201, Ino-4202, Ino-4212, Ino-4212 + Ino-9012, Ino-4201 + Ino-9012, Ino-1800, Ino-9112, Nucleos(T)Ide Analogue Treatment, Ino-3106, Ino-9012, Cellectra™-5P, Ino-3112, Vgx-6150, Ino-3401 + Ep, Vgx 3100, Cellectra™-5P, Vgx-3100, Vgx-3400X, Medpulser Electroporation With Bleomycin, Medpulser Electroporation With Bleomycin, Surgical Excision, Medpulser Electroporation With Bleomycin, Tumor Surgical Excision. These drug candidates are in various stages of clinical development as the company works toward FDA approval.